- Epoetin alfa increases the risk of serious cardiovascular events once the target hemoglobin level is greater than 11 g/dL or a rapid rise in hemoglobin (greater than 1 g/dL over two weeks of the period).

- Reports exist of erythema multiforme, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). Immediately discontinuation of the treatment is needed.

- Overdose of this medication is very rare — no antidote available at present.

- One case report describes an overdose of erythropoietin that caused essential erythrocytosis with the central nervous system and peripheral ischemia. The patient had successful treatment with emergent erythropheresis.